80 FR 54571 - Prospective Grant of a Start-up Exclusive Option License: Therapeutic Uses for Cardio-Metabolic Indications, Including Hypertriglyceridemia, Hypercholesterolemia and Diabetes

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 80, Issue 175 (September 10, 2015)

Page Range		54571-54572
FR Document		2015-22771

This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a Start-Up Exclusive Option License to practice the invention embodied in Patent Applications USSN 61/045,213, filed April 15, 2008; PCT/US2009/ 040560, filed April 14, 2009; and US 12/937,974, filed October 14, 2010, issued as 8,936,787 on January 20, 2015; titled ``Peptides Promoting Lipid Efflux'' (NIH Ref. E-138-2008/0) to Corvidia Corporation, having a place of business in Boston, MA. The patent rights in this invention have been assigned to the United States of America.

Federal Register, Volume 80 Issue 175 (Thursday, September 10, 2015)

[Federal Register Volume 80, Number 175 (Thursday, September 10, 2015)]
[Notices]
[Pages 54571-54572]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2015-22771]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of a Start-up Exclusive Option License: 
Therapeutic Uses for Cardio-Metabolic Indications, Including 
Hypertriglyceridemia, Hypercholesterolemia and Diabetes

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR 
part 404, that the National Institutes of Health (NIH), Department of 
Health and Human Services, is contemplating the grant of a

[[Page 54572]]

Start-Up Exclusive Option License to practice the invention embodied in 
Patent Applications USSN 61/045,213, filed April 15, 2008; PCT/US2009/
040560, filed April 14, 2009; and US 12/937,974, filed October 14, 
2010, issued as 8,936,787 on January 20, 2015; titled ``Peptides 
Promoting Lipid Efflux'' (NIH Ref. E-138-2008/0) to Corvidia 
Corporation, having a place of business in Boston, MA. The patent 
rights in this invention have been assigned to the United States of 
America.

DATES: Only written comments and/or application for a license that are 
received by the NIH Office of Technology Transfer on or before 
September 25, 2015 will be considered.

ADDRESSES: Requests for a copy of the patent application, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Cristina Thalhammer-Reyero, Ph.D., M.B.A., 
Office of Technology Transfer, National Institutes of Health, 6011 
Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Email: 
[email protected]; Telephone: 301-435-4507; Facsimile: 301-402-
0220.

SUPPLEMENTARY INFORMATION: The invention relates to compositions and 
methods for using multi-domain amphipathic [alpha]-helical peptides or 
peptide analogs to treat or inhibit dyslipidemic disorders. More 
specifically, the peptides and peptide analogs with multiple 
amphipathic [alpha]-helical domains: (a) Promote lipid efflux from 
cells via an ABCAl-dependent pathway; and (b) activate lipoprotein 
lipase.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 
404. The prospective exclusive option license may be granted unless, 
within 15 days from the date of this published Notice, NIH receives 
written evidence and argument that establishes that the grant of the 
license would not be consistent with the requirements of 35 U.S.C. 209 
and 37 CFR part 404.
    The field of use may be limited to ``Therapeutic uses for cardio-
metabolic indications, including hypertriglyceridemia, 
hypercholesterolemia and diabetes''.
    Properly filed competing applications for a license filed in 
response to this notice will be treated as objections to the 
contemplated license. Comments and objections submitted in response to 
this notice will not be made available for public inspection, and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: September 3, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology Transfer, National Institutes of 
Health.
[FR Doc. 2015-22771 Filed 9-9-15; 8:45 am]
BILLING CODE 4140-01-P

54572 Federal Register / Vol. 80, No. 175 / Thursday, September 10, 2015 / Notices

Start-Up Exclusive Option License to under the Freedom of Information Act, Dated: September 4, 2015.
practice the invention embodied in 5 U.S.C. 552. Melanie J. Gray,
Patent Applications USSN 61/045,213, Dated: September 3, 2015. Program Analyst, Office of Federal Advisory
filed April 15, 2008; PCT/US2009/ Richard U. Rodriguez, Committee Policy.
040560, filed April 14, 2009; and US 12/ [FR Doc. 2015–22802 Filed 9–9–15; 8:45 am]
Acting Director, Office of Technology
937,974, filed October 14, 2010, issued Transfer, National Institutes of Health. BILLING CODE 4140–01–P
as 8,936,787 on January 20, 2015; titled
[FR Doc. 2015–22771 Filed 9–9–15; 8:45 am]
‘‘Peptides Promoting Lipid Efflux’’ (NIH
BILLING CODE 4140–01–P
Ref. E–138–2008/0) to Corvidia DEPARTMENT OF HEALTH AND
Corporation, having a place of business HUMAN SERVICES
in Boston, MA. The patent rights in this DEPARTMENT OF HEALTH AND
invention have been assigned to the HUMAN SERVICES National Institutes of Health
United States of America.
DATES: Only written comments and/or National Institutes of Health National Institute of Mental Health;
application for a license that are Notice of Closed Meeting
received by the NIH Office of National Institute on Aging; Notice of
Technology Transfer on or before Closed Meetings Pursuant to section 10(d) of the
September 25, 2015 will be considered. Pursuant to section 10(d) of the Federal Advisory Committee Act, as
ADDRESSES: Requests for a copy of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is
patent application, inquiries, comments amended (5 U.S.C. App.), notice is hereby given of the following meeting.
and other materials relating to the hereby given of the following meetings. The meeting will be closed to the
contemplated license should be directed The meetings will be closed to the public in accordance with the
to: Cristina Thalhammer-Reyero, Ph.D., public in accordance with the provisions set forth in sections
M.B.A., Office of Technology Transfer, provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
National Institutes of Health, 6011 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and
Executive Boulevard, Suite 325, as amended. The grant applications and the discussions could disclose
Rockville, MD 20852–3804; Email: the discussions could disclose confidential trade secrets or commercial
ThalhamC@mail.nih.gov; Telephone: confidential trade secrets or commercial
property such as patentable material,
301–435–4507; Facsimile: 301–402– property such as patentable material,
and personal information concerning
0220. and personal information concerning
individuals associated with the grant individuals associated with the grant
SUPPLEMENTARY INFORMATION: The applications, the disclosure of which applications, the disclosure of which
invention relates to compositions and would constitute a clearly unwarranted would constitute a clearly unwarranted
methods for using multi-domain invasion of personal privacy. invasion of personal privacy.
amphipathic a-helical peptides or Name of Committee: National Institute of
peptide analogs to treat or inhibit Name of Committee: National Institute on
Aging Special Emphasis Panel; Alzheimer’s Mental Health Initial Review Group; Mental
dyslipidemic disorders. More Health Services Research Committee.
Disease Drug Development.
specifically, the peptides and peptide Date: October 8, 2015. Date: October 20, 2015.
analogs with multiple amphipathic a- Time: 1:00 a.m. to 4:30 p.m. Time: 8:30 a.m. to 12:00 p.m.
helical domains: (a) Promote lipid efflux Agenda: To review and evaluate grant Agenda: To review and evaluate grant
from cells via an ABCAl-dependent applications. applications.
pathway; and (b) activate lipoprotein Place: National Institute on Aging, Place: St. Gregory Hotel, 2033 M Street
lipase. Gateway Building, Suite 2C212, 7201
NW., Washington, DC 20036.
The prospective exclusive license will Wisconsin Avenue, Bethesda, MD 20892,
(Telephone Conference Call). Contact Person: Aileen Schulte, Ph.D.,
be royalty bearing and will comply with Contact Person: Alexander Parsadanian, Scientific Review Officer, Division of
the terms and conditions of 35 U.S.C. Ph.D., Scientific Review Officer National Extramural Activities, National Institute of
209 and 37 CFR part 404. The Institute On Aging Gateway Building 2C/212, Mental Health, NIH, Neuroscience Center,
prospective exclusive option license 7201 Wisconsin Avenue, Bethesda, MD 6001 Executive Blvd., Room 6136, MSC 9606,
may be granted unless, within 15 days 20892, 301–496–9666, PARSADANIANA@ Bethesda, MD 20852, 301–443–1225,
from the date of this published Notice, NIA.NIH.GOV. aschulte@mail.nih.gov.
NIH receives written evidence and Name of Committee: National Institute on (Catalogue of Federal Domestic Assistance
argument that establishes that the grant Aging Special Emphasis Panel; Circadian
Program No. 93.242, Mental Health Research
of the license would not be consistent Oscillators and Aging.
Date: October 21, 2015. Grants, National Institutes of Health, HHS)
with the requirements of 35 U.S.C. 209
Time: 12:00 p.m. to 3:00 p.m. Dated: September 3, 2015.
and 37 CFR part 404. Agenda: To review and evaluate grant
The field of use may be limited to Carolyn A. Baum,
applications.
‘‘Therapeutic uses for cardio-metabolic Place: National Institute on Aging, Program Analyst, Office of Federal Advisory
indications, including Gateway Building, Suite 2C212, 7201 Committee Policy.
hypertriglyceridemia, Wisconsin Avenue, Bethesda, MD 20892, [FR Doc. 2015–22766 Filed 9–9–15; 8:45 am]
hypercholesterolemia and diabetes’’. (Telephone Conference Call). BILLING CODE 4140–01–P
Contact Person: Alexander Parsadanian,
mstockstill on DSK4VPTVN1PROD with NOTICES

Properly filed competing applications
Ph.D. Scientific Review Officer National
for a license filed in response to this Institute On Aging Gateway Building 2C/212,
notice will be treated as objections to 7201 Wisconsin Avenue, Bethesda, MD
the contemplated license. Comments 20892, 301–496–9666, PARSADANIANA@
and objections submitted in response to NIA.NIH.GOV.
this notice will not be made available (Catalogue of Federal Domestic Assistance
for public inspection, and, to the extent Program Nos. 93.866, Aging Research,
permitted by law, will not be released National Institutes of Health, HHS)

VerDate Sep<11>2014 17:28 Sep 09, 2015 Jkt 235001 PO 00000 Frm 00062 Fmt 4703 Sfmt 9990 E:\FR\FM\10SEN1.SGM 10SEN1

Document Created: 2015-12-15 10:03:49
Document Modified: 2015-12-15 10:03:49

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Action		Notice.
Dates		Only written comments and/or application for a license that are received by the NIH Office of Technology Transfer on or before September 25, 2015 will be considered.
FR Citation		80 FR 54571

80 FR 54571 - Prospective Grant of a Start-up Exclusive Option License: Therapeutic Uses for Cardio-Metabolic Indications, Including Hypertriglyceridemia, Hypercholesterolemia and Diabetes

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 80, Issue 175 (September 10, 2015)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health